Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Theravance Biopharma has an average analyst rating of Moderate Buy from seven analysts (4 hold, 2 buy, 1 strong buy) with an average 1‑year price target of $22.60.
• Recent analyst activity is mixed—several downgrades and target cuts (e.g., B. Riley to $14, BTIG to $21, Oppenheimer to market perform) while HC Wainwright raised its target to $27—implying a broad $14–$27 target range.
• Institutional investors own 99.10% of the stock, with Vanguard, State Street, Geode and Dimensional boosting positions; the shares last traded at $13.58 within a 52‑week range of $7.90–$21.03 and a market cap of about $688 million.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $22.60.

A number of brokerages recently issued reports on TBPH. BTIG Research dropped their target price on shares of Theravance Biopharma from $40.00 to $21.00 and set a "buy" rating for the company in a research report on Tuesday. Wall Street Zen cut shares of Theravance Biopharma from a "strong-buy" rating to a "buy" rating in a research note on Saturday, January 3rd. B. Riley Financial reiterated a "neutral" rating and issued a $14.00 target price (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday. Oppenheimer downgraded Theravance Biopharma from an "outperform" rating to a "market perform" rating in a report on Thursday. Finally, HC Wainwright increased their price target on Theravance Biopharma from $20.00 to $27.00 and gave the stock a "buy" rating in a research report on Monday.

Institutional Trading of Theravance Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in TBPH. Vanguard Group Inc. lifted its position in Theravance Biopharma by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company's stock worth $32,289,000 after buying an additional 54,152 shares in the last quarter. State Street Corp raised its stake in shares of Theravance Biopharma by 4.4% in the fourth quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company's stock worth $20,616,000 after acquiring an additional 45,987 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Theravance Biopharma by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company's stock worth $17,567,000 after purchasing an additional 40,734 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Theravance Biopharma by 12.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company's stock valued at $16,072,000 after purchasing an additional 92,253 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Theravance Biopharma during the third quarter valued at approximately $10,611,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Price Performance

Shares of NASDAQ:TBPH opened at $13.58 on Friday. The business's fifty day moving average price is $19.06 and its two-hundred day moving average price is $16.83. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $21.03. The stock has a market capitalization of $688.10 million, a price-to-earnings ratio of 23.82 and a beta of 0.17.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.